CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:C-terminus CD28 phosphorylation (Y218) modulates IL-2 secretion and antitumor effect of CAR-T cells.
C-terminus CD28 phosphorylation (Y218) modulates IL-2 secretion and antitumor effect of CAR-T cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CD28是若干第二代嵌合抗原受体(CAR)T细胞的共刺激组成部分,可提供T细胞增殖、生存和细胞因子分泌所必需的信号。然而,CD28胞内各个基序对CAR-T 功能的具体贡献尚未充分阐明。
本研究发现,CD28胞质结构域中的酪氨酸218(Y218)是关键调控位点,并证实其磷酸化对CAR-T 发挥最佳活性至关重要。采用218F突变体后,研究显示Y218磷酸化缺失会损害IL-2生成并消除抗肿瘤疗效。218F CAR-T 转录组分析发现IL-17A、IL-17F及相关细胞因子表达升高,提示其表型可能转向促炎性Th17样状态并导致功能障碍。在机制上,研究证实白细胞介素-2诱导型T细胞激酶(ITK)介导Y218磷酸化。为进一步研究该激酶的作用,研究者构建了含ITK结合基序(PYRP)的新型CAR,可增强ITK募集、提高Y218磷酸化、促进IL-2分泌,并改善体内抗肿瘤疗效。研究强调Y218磷酸化对调节CAR-T 细胞命运的功能意义,并揭示通过靶向募集激酶微调CAR信号、增强治疗效力的策略。
CD28 is a co-stimulatory component of several second-generation chimeric antigen receptor (CAR)-T cells, providing signals essential for T cell proliferation, survival, and cytokine secretion.
However, the specific contribution of individual CD28 intracellular motifs to CAR-T cell function remains incompletely understood.
Here, we identify tyrosine 218 (Y218) in the CD28 cytoplasmic domain as a critical regulatory site, and demonstrate that its phosphorylation is essential for optimal CAR-T cell activity. Using a 218F mutant, we show that loss of Y218 phosphorylation leads to impaired IL-2 production and abrogates antitumor efficacy. Transcriptomic profiling of 218F CAR-T cells revealed increased expression of IL-17A, IL-17F, and related cytokines, suggesting a shift toward a pro-inflammatory Th17-like phenotype that may contribute to dysfunction.
Mechanistically, we demonstrate that the interleukin-2-inducible T-cell kinase, ITK, mediates Y218 phosphorylation. To further understand the role of this kinase, we engineered a novel CAR incorporating an ITK-binding motif (PYRP), which enhances ITK recruitment, increases Y218 phosphorylation, and boosts IL-2 secretion, and improves antitumor efficacy in vivo .
Our findings underscore the functional relevance of Y218 phosphorylation in modulating CAR-T cell fate and reveal a strategy to fine-tune CAR signaling through targeted kinase recruitment to enhance therapeutic efficacy.
MEMBER ACCOUNT
登录成功会直接打开下一页。